There were 21,162 patients randomised to placebo, ticagrelor 60 mg or ticagrelor 90 mg.
#Pegasus timi 54 trial
or 60 mg b.i.d., significantly reduced the risk of the composite of major adverse cardiovascular. The PEGASUS-TIMI 54 trial 5 assessed the efficacy and safety of ticagrelor 60 mg or 90 mg twice daily in patients with MI one to three years previously. The primary efficacy endpoint for the Pegasus-TIMI 54 study will be time to first occurrence of any cardiovascular event including CV death, non-fatal myocardial infarction or non-fatal stroke.ĪstraZeneca said that the Pegasus-TIMI 54 study is scheduled to begin patient enrolment during the fourth quarter 2010. In PEGASUS-TIMI 54, ticagrelor, at doses of either 90 mg b.i.d. In the Pegasus-TIMI 54 study patients will be randomised to either ticagrelor 60 or 90mg twice daily, or placebo and additionally, patients will also take once-daily, concomitant aspirin therapy (75 to 150mg). Pegasus-TIMI 54 is a randomised, double-blind, three-arm, parallel-group, international, multi-centre study which is expected to examine the long-term efficacy and safety of ticagrelor in patients who have sustained a heart attack from one to three years prior to enrolment. The Pegasus-TIMI 54 study aims to determine in this group of patients if treatment with ticagrelor and aspirin will further reduce the risk of subsequent cardiovascular events compared to aspirin alone.īrigham and Women’s cardiologist and TIMI Study Group vice chair and Pegasus-TIMI 54 principal investigator Marc Sabatine said that Pegasus-TIMI 54 would study treatment beyond 12 months after a heart attack, with dual antiplatelet therapy of ticagrelor and aspirin. The PEGASUS-TIMI 54 trial showed that among aspirin-treated individuals with prior MI, ticagrelor reduced cardiovascular events. Although the PEGASUS trial findings suggest an intriguing opportunity to improve outcomes of patients with prior MI, patients seen in routine clinical practice.
0 kommentar(er)
